Advertisement

Clinical Scenario: T2 Bladder Tumor

48-year-old healthy man with 4 cm, T2 urothelial carcinoma and negative metastatic evaluation who desires immediate cystectomy without neoadjuvant chemotherapy, erectile function preservation, and an ileal neobladder
  • Richard E. HautmannEmail author
Chapter

Abstract

The clinical scenario of a 48-year-old healthy man with 4 cm, T2 urothelial carcinoma and negative metastatic evaluation who desires immediate cystectomy without neoadjuvant chemotherapy, erectile function preservation, and an ileal neobladder is presented.

We recommend that cisplatinum-based neoadjuvant chemotherapy (NACT) be restricted to patients with undebated non-organ-confined urothelial BC (cT3, cT4a) and/or lymph node-positive disease (cNI). The chances of cure and of understaging are discussed with surgery, and capsule, prostate and seminal vesicle-sparing radical cystectomy (RC) is discussed as well as the high complication rates within 90 days of surgery (58 %) and long term (40 %). Postoperative care is outlined as well as differences in the robotic versus open approach and with a female patient.

Keywords

Bladder cancer Radical cystectomy Nerve sparing Chemotherapy 

References

  1. 1.
    Goossens-Laan CA, Visser O, Hulshof MC, Wouters MW, Bosch JL, Coebergh JW, Kil PJ. Survival after treatment for carcinoma invading bladder muscle: a Dutch population-based study on the impact of hospital volume. BJUI. 2011;110:226–32.CrossRefGoogle Scholar
  2. 2.
    International Bladder Cancer Nomogram Consortium. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol. 2006;24:3967–72.CrossRefGoogle Scholar
  3. 3.
    Mitra AP, Skinner EC, Miranda G, Daneshmand S. A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer. BJU Int. 2012;111:240–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Wosnitzer MS, Hruby GW, Murphy AM, Barlow LJ, Cordon-Cardo C, Mansukhani M, Petrylak DP, Benson MC, McKiernan JJ. A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aNO-N2MO bladder cancer. Cancer. 2012;118:358–64.PubMedCrossRefGoogle Scholar
  5. 5.
    Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, Crawford ED. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22:2781–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007;177:437–43.PubMedCrossRefGoogle Scholar
  7. 7.
    Hautmann RE, Stein JP. Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. Urol Clin N Am. 2005;32:177–85.CrossRefGoogle Scholar
  8. 8.
    Kiefer JC, Cherullo EE, Jones JS, Gong MC, Campbell SC. Prostate-sparing cystectomy: has Pandora’s box been opened? Expert Rev Anticancer Ther. 2007;7(7):1003–14.CrossRefGoogle Scholar
  9. 9.
    Hautmann RE, Hautmann O, Volkmer BG, Hautmann S. Nerve-sparing radical cystectomy: a new technique. Eur Urol Suppl. 2010;9:428–32.CrossRefGoogle Scholar
  10. 10.
    Hautmann RE, de Petriconi RC, Volkmer BG. Lessons learned from 1,000 neobladders: the 90-day complication rate. J Urol. 2010;184:990–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Hautmann RE, de Petriconi RC, Volkmer BG. 25 Years of experience with 1,000 neobladders: long-term complications. J Urol. 2011;185:2207–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Hautmann RE, Botto H, Studer UE. How to obtain good results with orthotopic bladder substitution: the 10 commandments. Eur Urol Suppl. 2009;8:712–7.CrossRefGoogle Scholar
  13. 13.
    Hautmann RE, Abol-Enein H, Davidsson T, Gudjonsson S, Hautmann SH, Holm HV, Lee CT, Liedberg F, Madersbacher S, Manoharan M, Mansson W, Mills RD, Penson DF, Skinner EC, Stein R, Studer UE, Thueroff JW, Turner WH, Volkmer BG, Abai X. ICUD-EAU international consultation on bladder cancer 2012: urinary diversion. Eur Urol. 2013;63:67–80.PubMedCrossRefGoogle Scholar
  14. 14.
    Hautmann RE. The oncologic results of laparoscopic radical cystectomy are not (yet) equivalent to open cystectomy. Curr Opin Urol. 2009;19:522–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Laudone V. Late breaking news: interim analysis of a prospective randomized trial comparing robotic and open cystectomy at memorial sloan-kettering cancer center. J Urol. 2013: 116.Google Scholar
  16. 16.
    Hautmann RE. The Ileal Neobladder. Atlas Urol Clin North Am. 2001;9(2):85.Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.University of UlmNeu-UlmGermany

Personalised recommendations